22 Apr 2026
22m
Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.